553 related articles for article (PubMed ID: 29929478)
1. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.
Tyagi P; Juma Z; Hor YK; Scott NW; Ionean A; Santiago C
BMC Ophthalmol; 2018 Jun; 18(1):148. PubMed ID: 29929478
[TBL] [Abstract][Full Text] [Related]
2. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration.
Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P
Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860
[TBL] [Abstract][Full Text] [Related]
4. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
[TBL] [Abstract][Full Text] [Related]
5. QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION.
Balaskas K; Karampelas M; Horani M; Hotu O; Keane P; Aslam T
Retina; 2017 Jul; 37(7):1297-1304. PubMed ID: 27755376
[TBL] [Abstract][Full Text] [Related]
6. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
8. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
[TBL] [Abstract][Full Text] [Related]
11. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
12. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
13. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
14. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of aflibercept in pigment epithelial detachments secondary to neovascular age related macular degeneration.
Diaconita V; Li B; Pal L; Bahnacy F; Gonder JR
Can J Ophthalmol; 2019 Oct; 54(5):626-634. PubMed ID: 31564356
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
[TBL] [Abstract][Full Text] [Related]
18. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
[TBL] [Abstract][Full Text] [Related]
19. [Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results].
Pfau M; Fassnacht-Riederle HM; Freiberg FJ; Wons JB; Wirth M; Becker MD; Michels S
Klin Monbl Augenheilkd; 2016 Aug; 233(8):945-50. PubMed ID: 27123887
[TBL] [Abstract][Full Text] [Related]
20. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.
Lotery A; Griner R; Ferreira A; Milnes F; Dugel P
Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
